Ann: Alterity Parkinson's and MSA Data Featured at AAN Meeting, page-12

As the company itself says today: "..........at ANN meeting". "Price sensitivity: No" There was nothing price sensitive info presented in this meeting.

We investors were waiting for concrete results about the open study as we thought there would be (on 20th of Feb: "Summary: Alterity to Present New Data at the AAN 2024 Annual Meeting"). Perhaps there was some "New Data" in the Stamlers presentation but not at all, what we waited for: some open study results.

Now when we have even seen the posters and not only the abstracts: Price sensitivity: No.

It looks now that we, the investors, and others made the rumors about the possible results we were waiting for. Maybe ATH434 is today more well known than before the meeting so the number of people waiting for the results is bigger and in the case of positive results, the reaction on the market is even stronger and more permanent than this time.